強直性脊椎炎の疫学的予測...市場調査レポートについてご紹介

1 Table of Contents
1 Table of Contents 4
1.1 List of Tables 6
1.2 List of Figures 7
2 Introduction 8
2.1 Catalyst 8
2.2 Related Reports 9
3 Epidemiology 10
3.1 Disease Background 10
3.2 Risk Factors and Comorbidities 12
3.3 Global Trends 13
3.3.1 US 16
3.3.2 5EU 16
3.3.3 Japan 17
3.4 Forecast Methodology 17
3.4.1 Sources Used for Diagnosed Prevalence of AS 20
3.4.2 Sources used for Diagnosed Prevalence of Nr-axSpA 22
3.4.3 Sources Used for the Prevalence of HLA-B27 Seropositivity in Diagnosed AS 23
3.4.4 Sources Not Used 25
3.4.5 Forecast Assumptions and Methods, Diagnosed Prevalent Cases of AS – Base Scenario 26
3.4.6 Forecast Assumptions and Methods, Diagnosed Prevalent Cases of Nr-axSpA – Base Scenario 28
3.4.7 Forecast Assumptions and Methods, HLA-B27 Seropositivity in Diagnosed AS 29
3.4.8 Forecast Assumptions and Methods, Diagnosed Prevalent Cases of AS – Alternative Scenario 30
3.4.9 Forecast Assumptions and Methods, Diagnosed Prevalent Cases of Nr-axSp – Alternative Scenario 30
3.5 Epidemiological Forecast for AS (2014-2024) – Base Scenario 31
3.5.1 Diagnosed Prevalent Cases of AS 31
3.5.2 Age-Specific Diagnosed Prevalent Cases of AS 32
3.5.3 Sex-Specific Diagnosed Prevalent Cases of AS 34
3.5.4 Age-Standardized Diagnosed Prevalence of AS 36
3.5.5 Diagnosed Prevalent Cases of Nr-axSpA 38
3.5.6 Prevalent Cases of HLA-B27 Seropositivity in Diagnosed AS Cases 39
3.6 Epidemiological Forecast for AS (2014-2024) – Alternative Scenario 42
3.6.1 Diagnosed Prevalent Cases of AS 42
3.6.2 Diagnosed Prevalent Cases of Nr-axSpA 43
3.7 Discussion 45
3.7.1 Epidemiological Forecast Insight 45
3.7.2 Limitations of the Analysis 46
3.7.3 Strengths of the Analysis 46
4 Appendix 48
4.1 Bibliography 48
4.2 About the Authors 53
4.2.1 Epidemiologists 53
4.2.2 Reviewers 53
4.2.3 Global Director of Therapy Analysis and Epidemiology 54
4.2.4 Global Head of Healthcare 55
4.3 About GlobalData 56
4.4 About EpiCast 56
4.5 Disclaimer 57